US3360503A
(en)
*
|
1963-04-09 |
1967-12-26 |
Du Pont |
Process for preparing poly(alpha, alpha-disubstituted beta-lactams)
|
DE2048080C3
(de)
*
|
1970-09-30 |
1979-11-29 |
Basf Ag, 6700 Ludwigshafen |
Verfahren zur Herstellung von N-substituierten 33-disubstituierten ß -Lactamen
|
EP0180398A1
(en)
|
1984-10-26 |
1986-05-07 |
The Regents Of The University Of California |
Synthesis of beta-lactam
|
CA1305177C
(en)
|
1987-06-30 |
1992-07-14 |
Yasufumi Ohfune |
Carboxycyclopropylglycine and process for producing the same
|
US4904681A
(en)
|
1987-12-01 |
1990-02-27 |
G. D. Searle & Co. |
D-cycloserine and its prodrugs as cognitive enhancers
|
EP0360390A1
(en)
|
1988-07-25 |
1990-03-28 |
Glaxo Group Limited |
Spirolactam derivatives
|
US5061721A
(en)
|
1989-03-15 |
1991-10-29 |
G. D. Searle & Co. |
Composition containing d-cycloserine and d-alanine for memory and learning enhancement or treatment of a cognitive or psychotic disorder
|
US5086072A
(en)
|
1990-06-18 |
1992-02-04 |
The United States Of America As Represented By The Department Of Health And Human Services |
Treatment of mood disorders with functional antagonists of the glycine/nmda receptor complex
|
US5350769A
(en)
|
1990-10-30 |
1994-09-27 |
Ss Pharmaceutical Co., Ltd. |
Antiinflammatory gel preparation
|
US5168103A
(en)
|
1991-01-22 |
1992-12-01 |
American Home Products Corporation |
[[2-(amino-3,4-dioxo-1-cyclobuten-1-yl) amino]alkyl]-acid derivatives
|
CA2058223A1
(en)
*
|
1991-12-20 |
1993-06-21 |
Bing-Yan Zhu |
Process for preparing beta-lactams
|
FR2692268B1
(fr)
|
1992-06-15 |
1994-08-19 |
Rhone Poulenc Rorer Sa |
Nouveaux polypeptides ayant une activité de récepteur NMDA, acides nucléiques codant pour ces polypeptides et utilisations.
|
SE9301667D0
(sv)
|
1993-05-14 |
1993-05-14 |
Kabi Pharmacia Ab |
New use
|
US5523323A
(en)
|
1993-09-14 |
1996-06-04 |
Maccecchini; Maria-Luisa |
Use of partial agonists of the NMDA receptor to reduce opiate induced tolerance and dependence
|
US5605911A
(en)
|
1995-01-31 |
1997-02-25 |
Washington University |
Use of alpha-2 adrenergic drugs to prevent adverse effects of NMDA receptor hypofunction (NRH)
|
US6335358B1
(en)
|
1995-04-12 |
2002-01-01 |
President And Fellows Of Harvard College |
Lactacystin analogs
|
US5741778A
(en)
|
1996-03-19 |
1998-04-21 |
Amgen Inc. |
Method for treating Huntington's disease using glial cell line-derived neurotrophic factor (GDNF) protein product
|
US5763393A
(en)
|
1996-05-17 |
1998-06-09 |
Neurotherapeutics L.P. |
Neuroactive peptides
|
CN1130372C
(zh)
|
1996-06-07 |
2003-12-10 |
曾尼卡有限公司 |
肽衍生物
|
AU3972797A
(en)
|
1996-08-02 |
1998-02-25 |
Zymogenetics Inc. |
Testis-specific insulin homolog polypeptides
|
US5902815A
(en)
|
1996-09-03 |
1999-05-11 |
Washington University |
Use of 5HT-2A serotonin agonists to prevent adverse effects of NMDA receptor hypofunction
|
JP3955345B2
(ja)
|
1996-09-27 |
2007-08-08 |
サントリー株式会社 |
新規アミノ酸ダイジハーベイン
|
AU1585999A
(en)
|
1997-11-12 |
1999-05-31 |
Neurotherapeutics |
Methods for the detection and treatment of disease using a glycosyltransferase
|
US5952389A
(en)
|
1998-01-13 |
1999-09-14 |
Synchroneuron |
Methods of treating tardive dyskinesia and other movement disorders
|
US6007841A
(en)
|
1998-03-13 |
1999-12-28 |
Algos Pharmaceutical Corporation |
Analgesic composition and method for treating pain
|
US6274314B1
(en)
|
1998-04-02 |
2001-08-14 |
Nyxis Neurotherapies, Inc. |
Diagnostic assay for the modified nucleosides pseudouridine, 7-methyladenosine, or 1-methyladenosine
|
US6197820B1
(en)
|
1998-04-06 |
2001-03-06 |
Uab Research Foundation |
Use of phenylglycine derivatives to decrease neuronal death caused by brain tumors and brain lesions
|
US6025471A
(en)
|
1998-06-03 |
2000-02-15 |
Deghenghi; Romano |
Diazaspiro, azepino and azabicyclo therapeutic peptides
|
WO2000027790A1
(en)
|
1998-11-11 |
2000-05-18 |
Smithkline Beecham P.L.C. |
Mutilin compounds
|
WO2000028090A2
(en)
|
1998-11-12 |
2000-05-18 |
Nyxis, Inc. |
Diagnostic assay for cancer
|
US20030064921A1
(en)
|
1999-10-27 |
2003-04-03 |
The Regents Of The University Of California |
Methods and compounds for modulating melanocortin receptor ligand binding and activity
|
AU1922301A
(en)
|
1999-11-17 |
2001-05-30 |
Nyxis Neurotherapies, Inc. |
Differential gene expression in cancer
|
WO2001057240A2
(en)
|
2000-02-01 |
2001-08-09 |
Agy Therapeutics, Inc. |
Interaction of nmda receptor with protein tyrosine phosphatase
|
JP2001261679A
(ja)
|
2000-03-21 |
2001-09-26 |
Mitsui Chemicals Inc |
ピロリジノン誘導体及びそれらの製造方法並びに該化合物を含有する医薬
|
AU2001268467A1
(en)
|
2000-06-14 |
2001-12-24 |
Nyxis Neurotherapies, Inc. |
Identification of genes and compounds for treatment of cancer
|
JP2004500874A
(ja)
|
2000-06-22 |
2004-01-15 |
ニクシス ニューロセラピーズ インコーポレーティッド |
低酸素症および関連状態の治療のための神経活性ペプチド
|
GB0018272D0
(en)
|
2000-07-25 |
2000-09-13 |
Vernalis Research Limited |
Chemical compounds IV
|
IL145209A0
(en)
|
2000-09-06 |
2002-06-30 |
Pfizer Prod Inc |
Pharmaceutical combinations for the treatment of stroke and traumatic brain injury
|
EP1186303A3
(en)
|
2000-09-06 |
2003-12-10 |
Pfizer Products Inc. |
Pharmaceutical combinations, for the treatment of stroke and traumatic brain injury, containing a neutrophil inhibiting factor and an selective NMDA-NR2B receptor antagonist
|
UA73619C2
(en)
|
2000-12-13 |
2005-08-15 |
Pfizer Prod Inc |
Stable pharmaceutical compositions of nmda receptor agonist (variants) and method of treatment
|
US20020142287A1
(en)
|
2000-12-14 |
2002-10-03 |
Hirotaka Yamamoto |
High throughput assay to detect inhibitors of the map kinase pathway
|
AU2002248553A1
(en)
|
2001-03-07 |
2002-09-24 |
Cognetix, Inc |
Linear y-carboxyglutamate rich conotoxins
|
WO2002072609A2
(en)
|
2001-03-12 |
2002-09-19 |
Nyxis Neurotherapies, Inc |
Neuroactive peptides for prevention and/or treatment of hypoxia and neuropathic pain
|
WO2003010540A1
(en)
|
2001-07-25 |
2003-02-06 |
Nyxis Neurotherapies, Inc. |
Method of identifying nmda-related agent
|
EP1519939B9
(en)
|
2002-07-05 |
2011-04-06 |
Targacept, Inc. |
N-aryl diazaspirocyclic compounds and methods of preparation and use thereof
|
US7273889B2
(en)
|
2002-09-25 |
2007-09-25 |
Innovative Drug Delivery Systems, Inc. |
NMDA receptor antagonist formulation with reduced neurotoxicity
|
AU2004232939A1
(en)
|
2003-04-17 |
2004-11-04 |
Merck Sharp & Dohme Corp. |
Heterocyclic cyclopentyl tetrahydroisoquinoline and tetrahydropyridopyridine modulators of chemokine receptor activity
|
WO2005007656A1
(en)
|
2003-07-18 |
2005-01-27 |
Virochem Pharma Inc. |
Spiro compounds and methods for the modulation of chemokine receptor activity
|
EP1660634A4
(en)
|
2003-08-08 |
2009-02-18 |
Burnham Inst |
P16-mediated regulation of NMDA receptors
|
US7662856B2
(en)
|
2003-08-29 |
2010-02-16 |
The University Of Houston System |
Compositions having antimycrobial activity including a hydroxamate or a hydroxamate and a hydroxlyamine
|
GB0323204D0
(en)
|
2003-10-03 |
2003-11-05 |
Novartis Ag |
Organic compounds
|
US20050096311A1
(en)
|
2003-10-30 |
2005-05-05 |
Cns Response |
Compositions and methods for treatment of nervous system disorders
|
JPWO2005047286A1
(ja)
|
2003-11-13 |
2007-05-31 |
小野薬品工業株式会社 |
スピロ複素環化合物
|
ES2359707T3
(es)
|
2004-01-08 |
2011-05-26 |
F. Hoffmann-La Roche Ag |
Derivados de diaza-espiropiperidina.
|
WO2006034196A1
(en)
|
2004-09-17 |
2006-03-30 |
Lifelike Biomatic Inc. |
Compositions for enhancing memory and methods therefor
|
CN101090902B
(zh)
|
2004-10-13 |
2013-05-29 |
默沙东公司 |
Cgrp受体拮抗剂
|
DE602006020353D1
(de)
|
2005-03-24 |
2011-04-07 |
Univ Emory |
Progesterone Dosierungsanweisung in der Behandlung einer traumatischen Verletzung des Gehirns
|
WO2007025141A2
(en)
|
2005-08-26 |
2007-03-01 |
Wisconsin Alumni Research Foundation |
Poly-beta-peptides from functionalized beta-lactam monomers and antibacterial compositions containing same
|
AR059224A1
(es)
|
2006-01-31 |
2008-03-19 |
Jerini Ag |
Compuestos para la inhibicion de integrinas y uso de estas
|
WO2007103719A2
(en)
|
2006-03-03 |
2007-09-13 |
Incyte Corporation |
MODULATORS OF 11-β HYDROXYL STEROID DEHYDROGENASE TYPE 1, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USING THE SAME
|
JP2010503677A
(ja)
|
2006-09-15 |
2010-02-04 |
シェーリング コーポレイション |
脂質代謝の障害を治療するためのアゼチジノン誘導体
|
JP2008188285A
(ja)
|
2007-02-06 |
2008-08-21 |
Bridgestone Corp |
バックパッド及び車両用シート
|
JP2010522194A
(ja)
|
2007-03-20 |
2010-07-01 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
キナーゼ阻害薬として有用なアミノピリミジン
|
CN101066945B
(zh)
|
2007-05-25 |
2010-05-19 |
中国科学院上海有机化学研究所 |
一种合成3-位取代内酰胺类化合物的方法
|
CN101125817B
(zh)
|
2007-08-03 |
2011-09-14 |
中国科学院上海有机化学研究所 |
一种合成高对映选择性醛基取代小环胺类化合物和光学活性3-位取代内酰胺类化合物的方法
|
US20090054392A1
(en)
|
2007-08-20 |
2009-02-26 |
Wyeth |
Naphthylpyrimidine, naphthylpyrazine and naphthylpyridazine analogs and their use as agonists of the wnt-beta-catenin cellular messaging system
|
WO2009039390A2
(en)
|
2007-09-20 |
2009-03-26 |
Naurex Inc. |
The development of glycobiology-based therapeutics for the treatment of brain tumors
|
WO2009105718A1
(en)
|
2008-02-20 |
2009-08-27 |
The Children's Hospital Of Philadelphia |
Genetic alterations associated with autism and the autistic phenotype and methods of use thereof for the diagnosis and treatmemt of autism
|
EP2293777B1
(en)
|
2008-06-24 |
2015-02-25 |
Intervet International B.V. |
Pharmaceutical transdermal compositions and method for treating inflammation in cattle
|
AU2009264334A1
(en)
|
2008-06-27 |
2009-12-30 |
Neurosearch A/S |
Novel tetramethyl substituted piperidine derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
|
ES2461841T3
(es)
|
2008-08-07 |
2014-05-21 |
F. Hoffmann-La Roche Ag |
Proceso para la preparación de un macrociclo
|
GB0814991D0
(en)
*
|
2008-08-15 |
2008-09-24 |
Glaxo Group Ltd |
Compounds
|
AU2009293164B2
(en)
|
2008-09-18 |
2015-07-09 |
Northwestern University |
NMDA receptor modulators and uses thereof
|
WO2010065709A2
(en)
|
2008-12-03 |
2010-06-10 |
Amin Khan |
Hydroxamic acid derivatives, preparation and therapeutic uses thereof
|
DE102009001460B4
(de)
|
2009-03-11 |
2010-12-02 |
Zf Friedrichshafen Ag |
Ölbehälter
|
US8329904B2
(en)
|
2009-05-12 |
2012-12-11 |
Hoffmann-La Roche Inc. |
Azacyclic derivatives
|
WO2011003064A2
(en)
|
2009-07-02 |
2011-01-06 |
Naurex, Inc. |
Methods of treating neuropathic pain
|
HUE043807T2
(hu)
|
2009-10-05 |
2019-09-30 |
Univ Northwestern |
GLYX Alzheimer-kór, Parkinson-kór vagy Huntington-kór kezelésében történõ alkalmazásra
|
US8951968B2
(en)
|
2009-10-05 |
2015-02-10 |
Northwestern University |
Methods of treating depression and other related diseases
|
US8871208B2
(en)
|
2009-12-04 |
2014-10-28 |
Abbvie Inc. |
11-β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitors and uses thereof
|
ES2459496T3
(es)
|
2009-12-21 |
2014-05-09 |
Novartis Ag |
Diaza-espiro[5.5]undecanos como antagonistas del receptor de orexina
|
KR101692275B1
(ko)
|
2010-02-11 |
2017-01-04 |
노오쓰웨스턴 유니버시티 |
2차 구조 안정화된 nmda 수용체 조절제 및 그의 용도
|
AU2011215704B2
(en)
|
2010-02-11 |
2015-07-23 |
Northwestern University |
Secondary structure stabilized NMDA receptor modulators and uses thereof
|
UY33227A
(es)
|
2010-02-19 |
2011-09-30 |
Novartis Ag |
Compuestos de pirrolopirimidina como inhibidores de la cdk4/6
|
US8097634B2
(en)
|
2010-04-15 |
2012-01-17 |
Hoffmann-La Roche Inc. |
Azacyclic derivatives
|
GB201007789D0
(en)
|
2010-05-10 |
2010-06-23 |
Glaxo Group Ltd |
Novel Compound
|
CN102267995A
(zh)
|
2010-06-04 |
2011-12-07 |
艾琪康医药科技(上海)有限公司 |
一种制备二氮杂螺环化合物的方法
|
WO2012021712A1
(en)
|
2010-08-12 |
2012-02-16 |
Tetraphase Pharmaceuticals, Inc. |
Tetracycline analogs
|
US9737531B2
(en)
|
2012-07-12 |
2017-08-22 |
Glytech, Llc |
Composition and method for treatment of depression and psychosis in humans
|
US9102671B2
(en)
|
2011-02-25 |
2015-08-11 |
Novartis Ag |
Compounds and compositions as TRK inhibitors
|
WO2012125598A1
(en)
|
2011-03-14 |
2012-09-20 |
Boehringer Ingelheim International Gmbh |
Benzodioxane inhibitors of leukotriene production
|
KR101309156B1
(ko)
*
|
2011-03-24 |
2013-09-17 |
삼성에스디아이 주식회사 |
리튬 이차 전지용 전해액 및 이를 포함하는 리튬 이차 전지
|
JP6035326B2
(ja)
|
2011-04-27 |
2016-11-30 |
ノースウェスタン ユニバーシティ |
アルツハイマー病、ハンチントン病、自閉症及びその他の疾患を治療する方法
|
EP2723506B1
(en)
|
2011-06-27 |
2017-02-15 |
Koninklijke Philips N.V. |
Ultrasound transducer assembly and method of manufacturing the same
|
EP2734299A4
(en)
|
2011-07-18 |
2016-05-11 |
Univ Alberta |
CATALYSTS AND METHODS FOR HYDROGENATION OF AMIDES
|
JP5427321B2
(ja)
|
2011-07-27 |
2014-02-26 |
アストラゼネカ アクチボラグ |
2−(2,4,5−置換−アニリノ)ピリミジン化合物
|
EP2796451B1
(en)
|
2011-12-20 |
2018-08-01 |
Wei Qian |
Heterocycle amido alkyloxy substituted quinazoline derivative and use thereof
|
AR092031A1
(es)
|
2012-07-26 |
2015-03-18 |
Merck Sharp & Dohme |
Inhibidores del canal de potasio medular externo renal
|
CN102936216B
(zh)
|
2012-12-05 |
2015-03-04 |
南京药石药物研发有限公司 |
7,9-二氧代-2,6-氮杂-螺[3.5]壬-2-甲酸叔丁酯及其中间体的制备方法
|
US9708335B2
(en)
*
|
2013-01-29 |
2017-07-18 |
Apytinyx Inc. |
Spiro-lactam NMDA receptor modulators and uses thereof
|
WO2014120784A1
(en)
|
2013-01-29 |
2014-08-07 |
Naurex, Inc. |
Spiro-lactam nmda receptor modulators and uses thereof
|
PE20151438A1
(es)
|
2013-01-29 |
2015-10-10 |
Naurex Inc |
Moduladores de receptores nmda de espiro-lactama y sus usos
|
BR112015018087B1
(pt)
|
2013-01-29 |
2022-09-20 |
Aptinyx Inc |
Compostos moduladores de receptor n-metil-d-aspartato (nmda) de espiro-lactama, composição farmacêutica e uso dos mesmos
|
CA2898863A1
(en)
|
2013-01-29 |
2014-08-07 |
Naurex, Inc. |
Spiro-lactam nmda receptor modulators and uses thereof
|
CN103171641B
(zh)
|
2013-03-19 |
2015-07-15 |
浙江大学 |
具备轮动功能的弹跳机器人
|
JO3517B1
(ar)
|
2014-01-17 |
2020-07-05 |
Novartis Ag |
ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2
|
TWI651310B
(zh)
*
|
2014-02-20 |
2019-02-21 |
日商日本煙草產業股份有限公司 |
三化合物及其醫藥用途
|
GB2528480A
(en)
|
2014-07-23 |
2016-01-27 |
Givaudan Sa |
Improvements in or relating to organic compounds
|
GB201416346D0
(en)
|
2014-09-16 |
2014-10-29 |
Shire Internat Gmbh |
Spirocyclic derivatives
|
WO2017201285A1
(en)
|
2016-05-19 |
2017-11-23 |
Aptinyx Inc. |
Spiro-lactam nmda receptor modulators and uses thereof
|
WO2017201283A1
(en)
|
2016-05-19 |
2017-11-23 |
Aptinyx Inc. |
Spiro-lactam nmda receptor modulators and uses thereof
|
SG11201900551WA
(en)
|
2016-08-01 |
2019-02-27 |
Aptinyx Inc |
Spiro-lactam nmda receptor modulators and uses thereof
|
PE20190502A1
(es)
|
2016-08-01 |
2019-04-10 |
Aptinyx Inc |
Moduladores del receptor nmda spiro-lactam y bis-spiro-lactam y uso de los mismos
|
PE20190500A1
(es)
|
2016-08-01 |
2019-04-10 |
Aptinyx Inc |
Moduladores del receptor nmda spiro-lactam y uso de los mismos
|
PE20190503A1
(es)
|
2016-08-01 |
2019-04-10 |
Aptinyx Inc |
Moduladores del receptor nmda espiro-lactam y uso de los mismos
|
PE20190501A1
(es)
|
2016-08-01 |
2019-04-10 |
Aptinyx Inc |
Moduladores nmda espiro-lactam y metodos de uso de los mismos
|
EP3746442A1
(en)
|
2018-01-31 |
2020-12-09 |
Aptinyx Inc. |
Spiro-lactam nmda receptor modulators and uses thereof
|
US11578072B2
(en)
|
2018-01-31 |
2023-02-14 |
Aptinyx Inc. |
Spiro-lactam NMDA receptor modulators and uses thereof
|
US20210308101A1
(en)
|
2019-11-11 |
2021-10-07 |
Aptinyx Inc. |
Methods of treating fibromyalgia
|
US20210139489A1
(en)
|
2019-11-11 |
2021-05-13 |
Aptinyx Inc. |
Methods of treating painful diabetic peripheral neuropathy
|
CA3161742A1
(en)
|
2019-12-04 |
2021-06-10 |
Aptinyx Inc. |
Methods of treating cognitive impairment associated with neurodegenerative disease
|